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The	cytokine	TGF-β	acts	as	a	tumor	suppressor	in	normal	epithelial	cells	and	during	the	early	stages	of	
tumorigenesis.	During	malignant	progression,	cancer	cells	can	switch	their	response	to	TGF-β	and	use	
this	cytokine	as	a	potent	oncogenic	factor;	however,	the	mechanistic	basis	for	this	is	poorly	understood.	
Here	we	demonstrate	that	downregulation	of	disabled	homolog	2	(DAB2)	gene	expression	via	promoter	
methylation	frequently	occurs	in	human	squamous	cell	carcinomas	(SCCs)	and	acts	as	an	independent	
predictor	of	metastasis	and	poor	prognosis.	Retrospective	microarray	analysis	in	an	independent	data	
set	indicated	that	low	levels	of	DAB2	and	high	levels	of	TGFB2	expression	correlate	with	poor	prognosis.	
Immunohistochemistry,	reexpression,	genetic	knockout,	and	RNAi	silencing	studies	demonstrated	that	
downregulation	of	DAB2	expression	modulated	the	TGF-β/Smad	pathway.	Simultaneously,	DAB2	down-
regulation	abrogated	TGF-β	tumor	suppressor	function,	while	enabling	TGF-β	tumor-promoting	activi-
ties.	Downregulation	of	DAB2	blocked	TGF-β–mediated	inhibition	of	cell	proliferation	and	migration	
and	enabled	TGF-β	to	promote	cell	motility,	anchorage-independent	growth,	and	tumor	growth	in	vivo.	
Our	data	indicate	that	DAB2	acts	as	a	tumor	suppressor	by	dictating	tumor	cell	TGF-β	responses,	identify	
a	biomarker	for	SCC	progression,	and	suggest	a	means	to	stratify	patients	with	advanced	SCC	who	may	
benefit	clinically	from	anti–TGF-β	therapies.
Introduction
TGF-β can act as both a potent tumor suppressor and tumor 
promoter in a context-dependent manner. TGF-β is considered 
the most potent and widespread inhibitor of cell growth known 
in mammals (1, 2), and resistance to TGF-β–mediated cytosta-
sis may represent one of the fundamental hallmarks of cancer 
(3, 4). In contrast, there is strong evidence that TGF-β–induced 
pro-oncogenic effects are a common feature of advanced malig-
nancies. TGF-β can operate to promote tumorigenesis via a 
combination of tumor-cell-autonomous and non–tumor-cell-
autonomous effects. These include promotion of tumor cell pro-
liferation, survival, motility, invasion, intravasation and extrava-
sation at distant metastatic sites, promotion of angiogenesis, and 
inhibition of the antitumor immune response (1, 2, 4, 5). In the 
later stages of carcinogenesis, specific genetic and/or epigenetic 
changes must occur in the cancer cell that “switch” its response 
to autocrine- or paracrine-secreted TGF-β, yet little is known of 
the identity of the genes affected by these changes (6, 7).
TGF-β elicits its biological effects by activation of the canonical 
Smad and non-Smad pathways (8, 9). TGF-β stimulation results 
in the activin-like kinase 5–mediated (ALK5-mediated) c-termi-
nal phosphorylation of the receptor-regulated Smads, Smad2 and 
Smad3. Following phosphorylation, Smad2 and Smad3 form het-
erooligomeric complexes with Smad4, accumulate in the nucleus, 
and regulate target gene expression (10). Efficient TGF-β–mediated 
Smad activation involves the action of intracellular adapter proteins, 
which facilitate the interaction of Smads with the activated receptor 
complex (11). These include Smad anchor for receptor activation 
(SARA) (12), cytoplasmic PML (13), and the p96 form of disabled 
homolog 2 (DAB2) (14). DAB2 is a multifunctional adapter protein, 
which acts as a regulator of clathrin-mediated endocytosis (15–18), 
and a negative regulator of multiple signaling pathways, includ-
ing the ERK/MAPK (19), Src (20), and Wnt pathways (21). DAB2 
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was originally identified as DOC2 a gene downregulated in ovarian 
carcinomas (22, 23). Subsequent studies have shown that DAB2 
downregulation occurs in prostate (24), breast (25), esophageal (26), 
endometrioid (27), urothelial (28), and hepatocellular carcinomas 
(29), suggesting that DAB2 has tumor suppressor activity.
Here we identify epigenetic transcriptional downregulation of 
DAB2 as a major determinant of metastatic progression and an inde-
pendent predictor of clinical outcome in squamous cell carcinoma 
(SCC). Furthermore, we provide a mechanistic explanation of the 
tumor suppressor function of DAB2 and demonstrate that down-
regulation of DAB2 switches TGF-β from a tumor suppressor to a 
tumor promoter in vitro and in vivo. These studies identify what 
we believe to be a novel biomarker for SCC progression and patient 
stratification for the use of anti–TGF-β–targeted therapies.
Results
DAB2 is epigenetically downregulated in squamous carcinoma cell lines. 
Using subtraction PCR techniques, we found that the DAB2 gene 
is frequently underexpressed in cDNA isolated from SCC cell lines 
compared with cDNA isolated from normal squamous epitheli-
um (data not shown). We therefore analyzed DAB2 expression by 
quantitative RT-PCR (qRT-PCR) (Figure 1A) and Western blotting 
(Figure 1, B and C) in a panel of head and neck SCC (HNSCC) (Fig-
ure 1B) and vulval SCC (VSCC) (Figure 1C) cell lines. We observed 
a low level of DAB2 expression in the VSCC cell lines UMSCV2, 
A431, McKenzie, and UMSCV6A and in the HNSCC cell lines 
HN5, HSC3, SCC25, and Delve, compared with the VSCC cell lines 
UMSCV1A, UMSCV1B, and UMSCV7 and the HNSCC cell lines 
H413, HN30, Proctor, H376, and HN76. Where tested, DAB2 pro-
tein levels mirrored DAB2 mRNA expression (Figure 1, B and C).
A CpG island is located at the 5ʹ end of the DAB2 gene (UCSC 
Genome Bioinformatics Site; http://genome.ucsc.edu/cgi-bin/
hgTracks?hgsid=71021636&hgt.right2=%3E%3E+Position= 
chr5%3A39408502-39460703), suggesting that transcriptional 
silencing of DAB2 might occur via aberrant promoter methylation 
in squamous carcinomas. We performed bisulphite sequencing 
analysis of the entire CpG island in the panel of SCC cell lines and 
of genomic DNA isolated from normal squamous keratinocytes 
(NKs) (Figure 1D). There was dense methylation in the HSC3, 
McKenzie, UMSCV6A, and Delve cell lines, consistent with down-
regulation of DAB2 expression, but the CpG island was entirely 
unmethylated in NKs and UMSCV1A, UMSCV1B, and UMSCV7 
cells, in which DAB2 was abundantly expressed. We could detect 
minimal to no methylation in the poorly expressing UMSCV2, 
A431, and SCC25 cell lines. Based on these analyses, we designed 
methylation-specific PCR (MSP) primers (illustrated in Figure 
1D; see Supplemental Methods; supplemental material available 
online with this article; doi:10.1172/JCI36125DS1), and MSP anal-
ysis was entirely consistent with bisulphite sequencing (Figure 1E). 
To further investigate the relationship between promoter methyla-
tion and DAB2 expression, we treated the low-level DAB2-express-
ing cell lines with 5-azacytidine, the histone deacetylase (HDAC) 
inhibitor trichostatin A (TSA), or both of these reagents (Supple-
mental Figure 1). qRT-PCR analysis of DAB2 mRNA expression 
after these treatments indicated that 5-azacytidine treatment was 
capable of restoring DAB2 expression in the HSC3, HN5, and A431 
cell lines. TSA treatment, either alone (HSC3, UMSCV2, and HN5) 
or in combination with 5-azacytidine (Delve and SCC25), was also 
able to restore DAB2 expression, indicating that HDAC-mediated 
chromatin modulation may also play a role in downregulation of 
DAB2 expression. Compilation of these analyses revealed that epi-
genetic mechanisms control DAB2 expression in these cell lines 
(Supplemental Table 1), with direct promoter methylation occur-
ring in 5 out of 8 of the low-level DAB2 expressors.
We next investigated whether different histone modifications at 
the DAB2 promoter could account for the low level of DAB2 expres-
sion (Supplemental Figure 2A) in the 3 cell lines that displayed 
minimal promoter methylation (A431, SCC25, and UMSCV2). 
Using quantitative ChIP assays, we determined the levels of 
histone H3 and histone H4 acetylation in 2 regions of the DAB2 
promoter (illustrated in Supplemental Figure 2B). Strikingly, we 
found that the level of DAB2 mRNA expression correlated with 
the amount of H3 and H4 acetylation (modifications associated 
with transcriptional activation; refs. 30 and 31) at both regions. 
The DAB2-expressing HN30 cell line exhibited markedly greater 
histone acetylation than the low-level DAB2-expressing cell lines. 
Minimal H3 and H4 acetylation was detected in the UMSCV2 cell 
line that expressed the lowest amount of DAB2 (Supplemental 
Figure 2, C and D). These findings are consistent with the hypoth-
esis that transcriptional silencing may play a role in downregula-
tion of DAB2 expression in these cell lines. Polycomb complexes 
are instrumental in transcriptional silencing in higher eukaryotes 
and operate in part via methylation and recognition of histone H3 
lysine 27 (32). We determined the level of H3K27 trimethylation 
(H3K27Me3) at the DAB2 promoter using ChIP analysis. Levels of 
H3K27Me3 were highest in the UMSCV2 cell line, enriched in the 
SCC25 cell line, and lowest in HN30 cells (Supplemental Figure 
2, E and F). In contrast, all cell lines displayed comparable enrich-
ment for the H3K27Me3 mark at the developmentally silenced 
γ-globin promoter (Supplemental Figure 2G). To extend these 
observations, we used of the compound 3-deazaneplanocin A 
(DZNep), which reduces protein levels of components of the cellu-
lar polycomb repressor 2 complex, including the methyltransferase 
EZH2 subunit, consequently acting as an inhibitor of H3K27Me3 
deposition (33). A 24-hour treatment with DZNep was sufficient 
to reduce EZH2 protein levels in all cell lines (Supplemental Fig-
ure 2H) but could only induce DAB2 expression in the silenced 
cell lines, with the level of induction reflecting the initial level of 
H3K27Me3 (Supplemental Figure 2, H and I). Taken together, our 
observations indicate that DAB2 expression is transcriptionally 
downregulated in SCC cell lines via DNA promoter methylation 
and/or polycomb complex repression.
DAB2 CpG island methylation predicts metastasis and poor clinical 
outcome in squamous carcinomas. We next asked whether DAB2 
promoter methylation also occurred in primary squamous 
carcinomas. Using MSP analysis, we were able to detect DAB2 
promoter methylation in 5 out of 9 archival genomic DNA 
samples isolated from advanced HNSCC primary tumors (Fig-
ure 2A). We then analyzed DAB2 expression in a small series of 
advanced HNSCC with 2 samples of patient-matched normal 
tissue. We assessed expression using semiquantitative RT-PCR 
and methylation in the CpG island using MSP and bisulphite 
sequencing. DAB2 mRNA was expressed in both samples of nor-
mal squamous epithelium (Figure 2B), and the CpG island was 
unmethylated (data not shown). DAB2 mRNA was downregu-
lated in 2 out of 5 cases, and there was methylation, detected 
by both MSP and bisulphite sequencing, in the same 2 cases 
(Figure 2B and data not shown). These studies indicate that 
the methylation-dependent epigenetic downregulation of DAB2 
seen in cell lines also operates in primary HNSCCs.
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Given our findings that DAB2 expression is lost in both HNSCC and 
VSCC cell lines, we next investigated whether DAB2 promoter methyla-
tion is also detectable in primary VSCC. We therefore performed MSP 
analysis on 26 VSCC primary tumor and matched normal vulval tis-
sue samples. DAB2 promoter methylation was detected in 1 out of 10 
primary tumor samples, of which the patients had no inguinal lymph 
node involvement, and in 11 out of 16 patients with metastatic dis-
ease but not in normal tissue samples (Figure 2C). Importantly, MSP 
analysis from the 16 nodal samples detected DAB2 promoter methyla-
tion in 13 out of 16 cases (Figure 2C). These data indicate that DAB2 
promoter methylation in VSCC is strongly associated with the devel-
opment of inguinal nodal disease (P = 0.0053, Fisher’s exact test).
Figure 1
DAB2 is epigenetically downregulated in squamous carcinoma cell lines. (A) qRT-PCR analysis of DAB2 mRNA expression in HNSCC and 
VSCC cell lines. RNA levels in UMSCV2 cells were assigned the arbitrary value of 1. Determinations were performed in triplicate. Mean ± SD 
(n = 2) are shown. (B and C) Western blot analysis of DAB2 expression in HNSCC (B) and VSCC cell lines (C). Samples in C were run on the 
same gel but were noncontiguous as indicated by the white line. DAB2 is indicated on the figure. The asterisk indicates cross-reactive nonspe-
cific bands. (D) Analysis of CpG island methylation in SCC cell lines and normal oral keratinocytes (NK). A schematic representation of the CpG 
island located at the 5ʹ end of the human DAB2 gene and each of the 53 CpG dinucleotides is shown. DAB2 promoter methylation determined 
by bisulphite sequencing is represented as a solid square. pyro, pyrosequencing. (E) MSP analysis of SCC cell lines using MSP primers depicted 
in D. U and M refer to unmethylated and methylated PCR reactions, respectively.
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We were interested to determine whether DAB2 expression and 
its epigenetic regulation might also affect the clinicopathological 
properties and outcome in HNSCC. We therefore performed a ret-
rospective analysis of 100 archival samples of locally advanced, stage 
3 and 4 inoperable HNSCCs. Methylation in the DAB2 CpG island 
was detected in 58 out of 100 cases (Table 1). The frequency of DAB2 
promoter methylation was significantly higher in patients with 
locoregional nodal metastases, compared with cases lacking nodal 
Figure 2
DAB2 promoter methylation correlates with low-level expression and predicts metastasis and poor clinical outcome in SCC. (A) Analysis of DAB2 
promoter methylation by MSP analysis in 9 HNSCC primary tumor isolates. (B) DAB2 promoter methylation correlates with low-level DAB2 expres-
sion. Analysis of DAB2 expression by RT-PCR in 2 normal (N) and 5 primary HNSCC tumor (T) samples. GAPDH RT-PCR is shown as a loading 
control. (C) DAB2 promoter methylation correlates with metastasis in VSCC. Graphical representation of DAB2 MSP analysis of 26 matched normal 
tissue and primary tumors isolated from VSCC patients. Primary tumor data is separated into patients with (16 patients) and without (10 patients) 
inguinal nodal involvement, and analysis of matched metastasis material is also shown. (D and E) DAB2 promoter methylation predicts poor clinical 
outcome in HNSCC. Log-rank survival analysis in HNSCC patients. The Kaplan-Meier curves show analyses of overall survival (D) and progres-
sion-free survival (E) in patients with HNSCC, as a function of DAB2 promoter methylation (methylated) or lacking methylation (unmethylated). The 
numbers under the graphs indicate the numbers of cases analyzed. (D) Overall survival is significantly worse in patients with tumors with methylation 
in the DAB2 promoter (P < 0.0001). (E) Progression-free survival is significantly worse in patients with tumors with methylation in the DAB2 promoter 
(P < 0.0001). (F) MSP analysis correlates with pyrosequencing analysis. HNSCC tumor samples were analyzed by MSP analysis as in A and by 
quantitative pyrosequencing of CpG dinucleotides 39–44 (depicted in Figure 1D). Data represent the average percentage of methylation at each 
CpG, and box plots are shown for MSP+ve and MSP–ve samples. (G) MSP analysis correlates with DAB2 expression levels. qRT-PCR analysis of 
DAB2 expression of samples is analyzed as in F. Expression levels are represented in relation to the highest expressing sample, which is assigned 
the arbitrary value of 1. (F and G) Data are analyzed by nonparametric Mann-Whitney statistics. In box plots, the 75th and 25th percentiles are 
represented by the top and bottom of the box, respectively. The horizontal lines refer to the mean. **P < 0.01.
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disease (Mantel-Haenszel c2 test = 14.67, P = 0.0001), and DAB2 pro-
moter methylation was also associated with poor response to radical 
chemoradiotherapy with cisplatin-containing chemotherapy regi-
mens (Kendall’s t-b test = –0.31, P = 0.0002; Table 1). Next, we asked 
whether clinical outcome in HNSCC was influenced by DAB2 pro-
moter methylation status. Log-rank analysis indicated that overall 
survival (Figure 2D) was significantly worse in patients with tumors 
with methylation in the DAB2 promoter (5-year sur-
vival rate, 9% [95% CI, 2%–19%] versus 80% [95% CI, 
67%–92%], log-rank c2 test = 38.54, P < 0.0001). While 
excluding grade due to missing data on 36% of patients, 
the significant predictive ability of DAB2 promoter 
methylation on overall survival was found to remain 
(hazard ratio [HR] 0.07 [95% CI, 0.03–0.15], log-rank 
c2 test = 39.11; P < 0.0001) in a Cox multivariate analy-
sis, including gender, age, performance status, EGFR, 
tumor size, presence of nodal disease, and tumor stage 
(Table 1). Similarly, progression-free survival (Figure 
2E) was significantly worse in patients with tumors 
with methylation in the DAB2 promoter (5-year pro-
gression-free survival rate, 10% [95% CI, 1%–20%] 
versus 66% [95% CI, 51%–81%], log-rank c2 test = 32.63, 
P < 0.0001). The significant predictive ability of DAB2 
promoter methylation on progression-free survival 
was found to remain in a Cox multivariate analysis, 
including gender, age, performance status, EGFR, 
tumor size, presence of nodal disease, and tumor stage 
(HR 0.1 [95% CI, 0.05–0.21] P < 0.0001).
Having established that detection of DAB2 CpG 
island methylation by MSP predicts poor survival in 
this retrospective study, we have initiated a prospec-
tive study of similar stage 3 and 4 inoperable HNSCC 
patient samples. We found that 8 out of 15 samples 
displayed DAB2 CpG island methylation as detected 
by MSP. We next interrogated these samples using 
pyrosequencing analysis of CpGs 39–44 (see Figure 
1D) to provide a quantitative determination of meth-
ylation in this primary patient material. Samples that 
were scored CpG methylation positive by MSP analy-
sis (MSP+ve) displayed a much higher mean percent-
age CpG methylation (Figure 2F). Samples that were 
MSP+ve had at least 10% and MSP–ve samples had less 
than 10% average methylation of CpGs 39–44 (Mann-
Whitney test [95% CI, 3.65–27.5], P = 0.0092). We next 
determined DAB2 mRNA expression levels by qRT-
PCR in these samples and found that MSP+ve samples 
display very low levels of DAB2 mRNA compared with 
MSP–ve samples (Figure 2G); MSP+ve samples had less 
than 0.2 and MSP–ve samples had more than 0.2 rela-
tive Dab2 mRNA expression levels (Mann-Whitney test 
[95% CI, –0.6659 – –0.1860], P = 0.0015). These data 
indicate that tumors that score positive for DAB2 pro-
moter methylation in the MSP assay have high levels of 
CpG methylation and low levels of DAB2 mRNA.
Downregulation of DAB2 mRNA and protein and 
upregulation of TGFB2 mRNA correlate with poor survival 
in HNSCC. Taken together, our studies in SCC primary 
tumor material indicate that methylation of the DAB2 
CpG island correlates with downregulation of DAB2 
mRNA, the presence of metastatic disease, and poor 
patient survival. We therefore reasoned that low-level DAB2 mRNA 
expression should correlate with poor survival. Retrospective surviv-
al data and tumor microarray gene expressions were available for 68 
patients from the UK with HNSCC (T stage 1–4, clinical stage I–III). 
We performed univariate Cox analysis for DAB2 expression in this 
data set, coupled with automated discretisation (34) to separate the 
data set into DAB2 “high” (n = 35) and DAB2 “low” (n = 33) expres-
Table 1
DAB2 promoter methylation correlates with nodal disease and poor clinical 
response in HNSCC
Characteristics	 Methylated	DAB2		 Unmethylated	DAB2		 P
	 	 promoter	(n	=	58)	 promoter	(n	=	42)
	 	 n	 %	 n	 %	
Age (yr)
 ≤50 15 26 9 21 0.78
 >50 43 74 33 79 
Sex
 Male 50 86 34 81 0.67
 Female 8 14 8 19 
Performance status
 0 27 47 20 48 0.99
 1, 2 31 53 22 52 
EGFR
 0, 1+ 20 34 17 40 0.32
 2+ 15 26 13 31 
 3+ 23 40 12 29 
Tumor size
 1 3 5 2 5 0.76
 2 11 19 6 14 
 3 11 19 13 31 
 4, 4a 33 57 21 50 
Nodal disease
 0 4 7 16 38 0.0001
 1 6 10 4 10 
 2 36 62 19 45 
 3 12 21 3 7 
Grade
 1 3 8 4 17 0.69
 2 24 60 12 50 
 3 13 32 8 33 
Stage
 III 4 7 9 21 0.07
 IV, IVa 54 93 33 79 
Chemotherapy
 PF 25 43 19 45 0.49
 PGEM 12 21 12 29 
 TPF 21 36 11 26 
Response
 CR 26 45 32 76 0.0002
 PR/SD 19 32 8 19 
 PD 5 9 0 0 
 TD 8 14 2 5 
MSP analysis in 100 HNSCC primary tumor samples is shown, with comparative statisti-
cal analysis between methylation-positive and -negative samples. Tumor size and nodal 
disease were assessed using TNM staging classification. Performance status “0” refers 
to asymptomatic patients and “1, 2” refers to symptomatic patients. EGFR “0, 1+” refers 
to absent or weak EGFR expression, “2+” refers to moderate EGFR expression, and 
“3+” refers to strong EGFR expression, as assessed during pathological examination. 
EGFR is also known as Her1. PF, cisplatin plus 5-fluorouracil; PGEM, cisplatin plus 
gemcitabine; TPF, paclitaxel and cisplatin plus 5-fluorouracil; CR, complete response; 
PR/SD, partial response/stable disease; PD, progressive disease; TD, terminal disease.
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sors. Kaplan-Meier analysis indicated that patients with low-level 
DAB2 expression had a significantly worse overall survival (low-level 
DAB2 expression, below average survival rate [referred to herein as 
DAB2 low average survival], 24.5 months, high-level DAB2 expres-
sion, above average survival rate [referred to herein as DAB2 high 
average survival], 31.8 months; log-rank c2 test = 4.42, P = 0.036; 
Figure 3A) and provided independent verification of our methyla-
tion studies. We next sought to determine whether DAB2 protein 
levels correlate with survival in HNSCC patients. We performed 
immunohistochemistry for DAB2 on an HNSCC tissue microarray 
(TMA), which contained a subset of the microarray samples (35). 
Using the weighted histoscore system, we observed a wide range of 
DAB2 expression in this TMA (Supplemental Figure 3). Importantly, 
and consistent with the microarray analysis, we found that patients 
with low-level DAB2 protein expression (histoscore, <70) had a sig-
nificantly worse overall survival (DAB2 low average survival, 25.03 
months, DAB2 high average survival, 36.62 months; log-rank c2 
test = 4.54, P = 0.033; Figure 3B). Overall survival decreased further 
still with even lower DAB2 expression (histoscore, <40; DAB2 low 
average survival, 20.61 months, DAB2 high average survival, 35.22 
months; log-rank c2 test = 7.04, P = 0.008; Supplemental Figure 4). 
All of these analyses indicate that a decrease in DAB2 expression 
correlates with poor survival in HNSCC.
Recent observations have indicated that DAB2 may play a role 
in TGF-β signaling (14, 36, 37). We therefore investigated whether 
changes in TGFB mRNA levels correlated with patient survival, 
using automated discretisation analysis on the microarray data set, 
with probe sets for TGFB1, TGFB2, and TGFB3. Patients expressing 
high levels of TGFB1 and TGFB3 appeared to fare worse, although 
this failed to reach statistical significance (Supplemental Figure 5). 
However, patients expressing high-level TGFB2 (n = 48) exhibited a 
statistically significantly worse overall survival than patients clas-
sified as TGFB2 low (n = 20) (TGFB2 high average survival, 25.6 
months, TGFB2 low average survival, 34.9 months; log-rank c2 
test = 4.68, P = 0.03; Figure 3C). Combination of the 2 TGFB2 groups 
with the 2 DAB2 groups created 4 groups (TGFB2 low, DAB2 high, 
Figure 3
Low-level DAB2 and high-level TGFB2 expression correlate with poor survival in HNSCC. (A, C, and D) Microarray analyses of 68 primary 
HNSCC tumor samples were assessed for expression of DAB2 (A), TGFB2 (C), and both (D). Tumor samples were separated after automated 
discretization into high- and low-level groups, and overall patient survival was assessed using univariate Cox and Kaplan-Meier survival analysis. 
(A) Low-level DAB2 mRNA expression correlates with poor survival (P = 0.036). (B) A subset of tumors analyzed in A were assessed for DAB2 
protein levels by immunohistochemistry and histoscore analysis. Patients were separated into high-level groups (DAB2 histoscore, >70) and 
DAB2 low-level groups, and overall patient survival was assessed using univariate Cox and Kaplan-Meier survival analysis. Low-level DAB2 
protein expression correlates with poor survival (P = 0.033). (C) High-level TGFB2 mRNA expression correlates with poor survival (P = 0.03). (D) 
Patients harboring tumors that express low-level DAB2 mRNA and high-level TGFB2 mRNA have the worst prognosis (P = 0.035).
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n = 10; TGFB2 low, DAB2 low, n = 10; TGFB2 high, DAB2 high, n = 25; 
TGFB2 high, DAB2 low, n = 23) that have significantly different 
survival prognosis (log-rank c2 test = 8.62, P = 0.035; Figure 3D). 
Importantly, this analysis indicated that patients who express 
high-level TGFB2 and low-level DAB2 had the worst prognosis 
(average survival, 23.9 months; Figure 3D), suggesting that loss of 
DAB2 may possibly modulate TGF-β signaling.
Loss of DAB2 expression does not preclude Smad2 or Smad3 activation. 
In HT1080 fibrosarcoma cells, DAB2 acts as an essential adapter, 
linking Smad2, Smad3, and the TGF-β receptor complex (14). We 
determined the ability of TGF-β to stimulate phosphorylation of 
Smad2 and Smad3 in the SCC cell lines (Figure 4, A and B). Unex-
pectedly, TGF-β clearly stimulated Smad2 phosphorylation in 
all cell lines tested, irrespective of DAB2 expression levels (Figure 
4, A and B). For example, in HSC3, which lacks detectable endog-
enous DAB2 due to dense CpG methylation, there was reproduc-
ibly robust TGF-β–mediated Smad2 activation. Similarly, TGF-β 
stimulated Smad3 phosphorylation in all of the cell lines apart 
from the UMSCV2 and HN5 cell lines, which express very low levels 
of endogenous Smad3 (Figure 4, A and B). Consistent with these 
results, immunofluorescence analysis revealed that TGF-β treat-
ment resulted in nuclear accumulation of Smad2/3 irrespective of 
DAB2 status (Supplemental Figure 6). These findings indicate that 
TGF-β–dependent activation of Smad2/Smad3 occurs in SCC cell 
lines, even in the absence of detectable endogenous DAB2 protein. 
To formally address whether DAB2 expression is absolutely required 
for Smad phosphorylation, we genetically deleted Dab2 expression 
in mouse embryonic fibroblasts (MEFs) isolated from Dab2Fl/– mice 
(16) by infection with a retroviral expression vector for Cre recom-
binase. Western blotting analysis revealed that, despite complete 
loss of Dab2 expression, these MEFs were capable of activating both 
Smad2 and Smad3 following TGF-β stimulation and, if anything, 
exhibited a slightly longer phospho-Smad2 response when com-
pared with control vector–infected cells (Supplemental Figure 7).
DAB2 suppresses TGF-β–mediated Smad2 activation. Next, we assessed 
the effect of inhibiting or restoring DAB2 expression on Smad acti-
vation in the SCC cell lines. Time course analysis following siRNA 
knockdown of DAB2 expression in UMSCV1B cells (Figure 4C) and 
HN30 cells (Supplemental Figure 8A) revealed that TGF-β stimula-
tion of Smad2 phosphorylation was markedly enhanced, whereas 
Smad3 activation was unaffected in knockdown cells, compared 
with negative control nonsilencing siRNA-transfected cells (Fig-
ure 4C and Supplemental Figure 8A). We next examined the effect 
of restoring DAB2 expression on Smad activation. We generated 
stable cell lines expressing Flag-tagged DAB2 in the A431 VSCC 
cell line and in the SKOV3 ovarian carcinoma cell line, previously 
identified as expressing low levels of DAB2 (22). We generated 2 
A431 (A431D2#1 and A431D2#2) and 2 SKOV3 (SKOV3D2#1 and 
SKOV3D2#2) cell lines, in which DAB2 expression was higher than 
parental and corresponding vector control (A431V and SKOV3V) 
cell lines, as assessed by Western blotting (Supplemental Figure 8B). 
Time course analysis of Smad activation following TGF-β treat-
ment revealed the opposite effects observed in the siRNA experi-
ments. DAB2 reexpression markedly inhibited TGF-β–dependent 
Smad2 phosphorylation in both the A431D2#1 and SKOV3D#1 
cell lines, compared with the corresponding vector control cell lines 
A431V and SKOV3V, while having little effect on relative Smad3 
phosphorylation (Figure 4D and Supplemental Figure 8C). Simi-
lar effects were observed in the A431D2#2 and SKOV3D2#2 cell 
lines (data not shown). We next assessed the ability of TGF-β to 
regulate target gene expression in the A431D2#1 and A431V cell 
lines. TGF-β induced expression of the Smad3/Smad4 target genes 
junB and Smad7 (38, 39) equally in both cell lines. Recently, it has 
been shown that TGF-β induces expression of SnoN in a Smad2-
dependent fashion (40). Consistent with this observation, we found 
that TGF-β stimulated SnoN expression in the A431V cell line but 
failed to do so in the A431D2#1 cell line (Supplemental Figure 9). 
Interestingly, we also observed similar regulation of the CXCR4 
gene (Supplemental Figure 9). These studies indicate that in SCC 
cell lines DAB2 acts to repress Smad2 activation. We next sought 
to determine whether this also occurs in primary patient samples 
in vivo. We first optimized phospho-Smad2 staining using West-
ern blotting and formalin-fixed, paraffin-embedded cell pellets of 
cells treated with and without the ALK5 inhibitor SB-431542 (41) 
and with and without TGF-β (Supplemental Figure 10). We next 
stained serial sections of a commercially available TMA contain-
ing samples from 18 HNSCC patients with both the DAB2 and 
phospho-Smad2 antibodies and analyzed expression levels using 
weighted histoscore analysis. Twelve of the eighteen tumors on this 
array exhibited low-level DAB2 staining (histoscore, <70). These 
tumors exhibited a higher level of phospho-Smad2 staining when 
compared with the tumors expressing a high level of DAB2 protein 
(Mann-Whitney test [95% CI, 0.03–110] P = 0.044; Figure 4E). Fur-
thermore, we frequently observed many areas of tumors that con-
tained inversely correlated levels of staining, showing either a high 
level of DAB2 staining or a high level of phospho-Smad2 staining 
(examples shown in Figure 4F). These findings are consistent with 
our cell line studies and suggest that in SCC tumors DAB2 can act 
as a suppressor of Smad2 activation.
DAB2 loss correlates with loss of TGF-β–dependent growth suppression. 
Having established that DAB2 acts as an endogenous inhibitor of 
TGF-β–mediated Smad2 phosphorylation, we wished to investi-
gate the consequences of DAB2 downregulation on TGF-β–driven 
biological responses. We first investigated whether DAB2 expres-
Figure 4
DAB2 represses TGF-β–mediated Smad2 activation. (A and B) Low-
level DAB2 expression does not preclude Smad2 and Smad3 phos-
phorylation. VSCC cell lines (A) and HNSCC cell lines (B) were treated 
for 1 hour with or without 1 ng/ml TGF-β prior to Western blotting for 
activation of Smad2 and Smad3, using PO4-Smad2 and PO4-Smad3 
antibodies. DAB2, Smad2, and Smad3 Western blotting analysis 
is also shown. (C) siRNA-mediated knockdown of DAB2 enhances 
TGF-β–mediated Smad2 activation. Western blotting analysis of 
TGF-β–mediated activation of Smad2 and Smad3 phosphorylation in 
UMSCV1B cells, following transient siRNA transfection with nonsilenc-
ing control (negative) and DAB2-specific siRNA (DAB2 s#1) and TGF-β 
treatment (1 ng/ml) for the indicated time points. Knockdown of DAB2 
was assessed by DAB2 Western blotting, and analysis of PO4-Smad2, 
PO4-Smad3, total Smad2, and Smad3 levels is shown. (D) DAB2 sta-
ble reexpression inhibits TGF-β–mediated Smad2 activation. West-
ern blotting analysis of A431 vector control (V) and Dab2 stable cell 
lines (A431D2#1 [D] analyzed as in C). (E and F) DAB2 protein levels 
inversely correlate with PO4-Smad2 levels. Serial sections of a HNSCC 
TMA were stained with DAB2 and PO4-Smad2 antibodies, respectively, 
and protein levels were determined by histoscore. DAB2 low sam-
ples (histoscore, <70) have a higher level of PO4-Smad2 (*P < 0.05) 
than DAB2 high samples. In box plots, the 75th and 25th percentiles 
are represented by the top and bottom of the box, respectively. The 
horizontal lines refer to the mean. (F) Regions of serial sections of 
3 example tumor TMA cores stained with the indicated antibodies, 
revealing mutually exclusive staining. Original magnification, ×20.
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Figure 5
DAB2 levels correlate with TGF-β responses in SCC cell lines. (A and B) Cell lines were treated with 1 ng/ml TGF-β for 48 hours, and [3H]thymidine 
incorporation assays were performed. Results are represented as the relative [3H]thymidine incorporation, where untreated samples are assigned 
an arbitrary mean value of 1. Data are represented as mean ± SD (n = 3). TGF-β inhibits proliferation in cell lines that express high levels of DAB2 
(A) but does not in cell lines that express low levels of DAB2 (B). (C and D). Indicated cell lines were grown to confluency and serum starved, 
and then scratch assays were performed and cell motility was monitored using time lapse microscopy. Unstimulated directional motility rates 
were assigned an arbitrary mean value of 1. Data are represented as the mean ± SD (n = 6). TGF-β inhibits motility in cell lines that express high 
levels of DAB2 (C) and promotes motility in cell lines that express low levels of DAB2 (D). (E and F) TGF-β promotes anchorage-independent 
growth in cell lines with low-level DAB2 expression. (E) Representative images of soft agar assays from the indicated cell lines untreated (–) or 
treated with TGF-β. Scale bar: 0.5 mm. (F) Graphical analysis of soft agar assays. Data represent the mean ± SD (n = 3). Statistical analyses 
were performed with paired 2 tailed t tests throughout. *P < 0.05, **P < 0.01, ***P < 0.001.
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Figure 6
Knockdown of DAB2 switches the TGF-β response. (A and B) Western blot analysis of DAB2 expression following siRNA-mediated knockdown 
of DAB2 expression with 2 different siRNAs (DAB2 s#1, DAB2 s#2) or a nonsilencing control siRNA (negative) in HN30 (A) and UMSCV1B cells 
(B). The asterisk denotes cross-reactive bands, which serve as loading controls in A, B, and G. Cells were transfected with the indicated siRNAs, 
and after 24 hours were seeded into separate dishes for wound-healing scratch assay analysis and [3H]thymidine incorporation assays. Whole cell 
lysates were prepared after the completion of the scratch assays, and Western blot analysis is shown from a representative experiment. (C and 
D) [3H]thymidine analysis performed and analyzed as in Figure 5. Knockdown of DAB2 blocks TGF-β–mediated proliferative arrest in HN30 (C) 
and UMSCV1B cells (D). (E and F) Wound-healing scratch motility assays performed and analyzed as described in Figure 5. Knockdown of DAB2 
switches the TGF-β response from inhibition to promotion of motility in HN30 (E) and UMSCV1B cells (F). (G and H) Knockdown of DAB2 per-
mits TGF-β–promoted anchorage-independent growth in UMSCV1A cells. Cells were transiently transfected with the indicated siRNAs and then 
seeded for Western blot analysis (G) or into soft agar assays with or without 1 ng/ml TGF-β (H). The total number of colonies per well is shown. 
Mean ± SD (n = 3) is shown throughout. Statistical analyses were performed with paired 2 tailed t tests throughout. *P < 0.05, **P < 0.01.
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sion affects the cytostatic response to TGF-β in our SCC cell line 
panel. Cell lines lacking DAB2 promoter methylation and that 
express high levels of DAB2 universally responded to TGF-β treat-
ment by a decrease in DNA synthesis (Figure 5A) and an inhibi-
tion of cell proliferation (Supplemental Figure 11). In contrast, 
cell lines expressing low or undetectable levels of DAB2 failed to 
exhibit a decrease in DNA synthesis (Figure 5B) and exhibited an 
increase (HN5), no change (HSC3, UMSCV2, and A431), or a mod-
est decrease (UMSCV6A, SCC25, and McKenzie) in proliferation 
(Supplemental Figure 12).
TGF-β–mediated regulation of cell motility and anchorage-indepen-
dent growth correlates with DAB2 expression levels. We next assessed 
the effect of DAB2 expression on TGF-β–mediated regulation of 
cell motility in quantitative wound-healing scratch assays. TGF-β 
inhibited cell motility in the majority of DAB2-expressing lines 
analyzed (Figure 5C). In contrast, TGF-β induced a 5-fold stimu-
lation of the motility rate in HN5 and a modest but statistically 
significant increase in motility rate in all other cell lines expressing 
low levels of DAB2 (Figure 5D).
TGF-β was originally identified by virtue of its ability to pro-
mote anchorage-independent growth of transformed fibroblasts 
(42, 43). We seeded the entire SCC cell line panel into soft agar and 
assessed their ability to grow in an anchorage-independent fash-
ion. Only cell lines expressing low levels of DAB2 formed colonies 
in soft agar, and TGF-β treatment increased anchorage-indepen-
dent growth in each case (Figure 5, E and F).
Silencing of DAB2 blocks TGF-β–mediated cytostasis, switches the TGF-β 
motility response, and promotes anchorage-independent growth. Our results 
imply that DAB2 expression levels dictate the TGF-β response 
of SCC cell lines and that DAB2 is required for TGF-β–mediated 
tumor suppressive effects. We used siRNA to knockdown DAB2 
expression in both HNSCC and VSCC cell lines to test these hypoth-
eses. We achieved modest knockdown with one siRNA (DAB2s#1) 
and more efficient knockdown with a second siRNA (DAB2s#2) 
in transiently transfected HN30 (Figure 6A) and UMSCV1B (Fig-
ure 6B) cells. The level of DAB2 expression correlated closely with 
the degree of TGF-β–mediated inhibition of DNA synthesis, with 
efficient knockdown completely abrogating this response (Fig-
ure 6, C and D). We next assessed the effect of DAB2 silencing on 
TGF-β–mediated regulation of cell motility, using the quantitative 
wound-healing assay. In both the HN30 and UMSCV1B cell lines, 
knockdown of DAB2 switched the TGF-β response from inhibi-
tion to promotion of cell motility (Figure 6, E and F). Finally, we 
investigated the effect of DAB2 knockdown on the ability of the 
UMSCV1A cell line to grow in soft agar. Knockdown of DAB2 (Fig-
ure 6G) both promoted and enabled TGF-β–mediated stimulation 
of anchorage-independent growth (Figure 6H).
Reexpression of DAB2 switches TGF-β from a tumor promoter to tumor 
suppressor. We next performed reciprocal experiments by ectopic 
expression in cell lines with low endogenous levels of DAB2. We 
generated an A431 TetOn cell line and derivatives that expressed 
a high level of DAB2 (A431 TDAB2#1) and a lower level of DAB2 
(A431 TDAB2#2) following doxycycline treatment (Figure 7A). 
Treatment of the A431 and A431 TetOn cell lines with TGF-β 
resulted in a modest increase in cell proliferation (Supplemental 
Figure 13). The leakier A431 TDAB2#1–inducible cell line failed to 
exhibit this increase, and cotreatment of the A431 TDAB2#1 cell 
line with TGF-β and doxycycline restored the ability of TGF-β to 
inhibit cell proliferation and abrogated this increase in the A431 
TDAB2#2 cell line (Supplemental Figure 13), indicating that under 
these conditions a high level of DAB2 expression is required for 
TGF-β–mediated cytostasis. We next assessed the ability of these 
cell lines to respond to TGF-β and grow in an anchorage-indepen-
dent manner. Consistent with our earlier findings, both the A431 
and A431 TetOn cell lines readily formed colonies in soft agar, and 
TGF-β treatment enhanced anchorage-independent growth (Fig-
ure 7B). Both DAB2-inducible cell lines were able to form colonies 
in soft agar to a similar degree to that of the A431 cell line but fewer 
than the parental A431 TetOn cell line. Both cell lines switched 
their response to TGF-β, with TGF-β treatment now acting to 
inhibit anchorage-independent growth in a DAB2 expression level–
dependent fashion (Figure 7B). TGF-β treatment inhibited colony 
formation in the A431 TDAB2#1 cell line, even in the absence of 
doxycycline, whereas TGF-β only inhibited colony formation in 
the A431 TDAB2#2 cell line in the presence of doxycycline. These 
findings indicate that a level of DAB2 expression above the baseline 
expression observed in the A431 TDAB2#2 cell line but less than or 
equal to the baseline expression observed in the A431 TDAB2#1 cell 
line is required to restore this activity of TGF-β.
We recapitulated these findings in the A431 and SKOV3 cell 
lines stably expressing Flag-tagged DAB2. Soft agar analysis 
revealed that TGF-β promoted anchorage-independent growth in 
the parental and vector control cell lines, whereas enforced DAB2 
expression switched this response as TGF-β inhibited colony for-
mation in all 4 DAB2-expressing cell lines (Figure 7C). Wound-
healing analysis demonstrated that TGF-β readily stimulated cell 
motility in the A431 and A431V cell lines and modestly stimulated 
cell motility in the SKOV3V cell line. In each of the cell lines ectopi-
cally expressing DAB2, TGF-β treatment now efficiently inhibited 
cell motility (Figure 7D).
Together, these results indicate that restoration of DAB2 expres-
sion to carcinoma cell lines of either squamous (A431) or glan-
dular origin (SKOV3) switches the TGF-β response from tumor 
promoting to tumor suppressing. We next tested whether similar 
effects occur in vivo. A431V and A431D2#1 cell lines were pretreat-
ed for 4 days with or without TGF-β, harvested, and mixed, with 
or without TGF-β, and then equal numbers of cells were injected 
subcutaneously into the flanks of CD1 nude mice. We observed 
that TGF-β acted as a tumor promoter in the A431V cell line and 
enhanced tumor growth (Figure 7E). In contrast, restoration of 
DAB2 expression abrogated the protumorigenic effects of TGF-β, 
and, if anything, TGF-β–treated A431D2#1-derived tumors pro-
liferated at a slower rate, although this failed to reach statistical 
significance (Figure 7F).
Discussion
We identified DAB2 as a candidate tumor suppressor in SCC, using 
subtraction hybridization techniques. These results are consistent 
with previous observations, demonstrating that DAB2 is downreg-
ulated in numerous other human tumor types (22–29). Analysis 
of the promoter region of the DAB2 gene revealed the presence of 
53 CpG dinucleotides within a predicted CpG island, prompting 
to us to investigate aberrant promoter methylation as a poten-
tial mechanism of DAB2 silencing. Using bisulphite sequencing 
and MSP analysis, we found that hypermethylation of the DAB2 
promoter correlated with low-level DAB2 expression in HNSCC 
and VSCC cell lines. In a subset of cell lines, we also found that 
polycomb-mediated repression may contribute to DAB2 down-
regulation. Importantly our MSP studies in primary tumor tissue 
revealed that DAB2 promoter methylation acted as a predictor of 
Downloaded on June 10, 2013.   The Journal of Clinical Investigation.   More information at  www.jci.org/articles/view/36125
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 120   Number 8   August 2010 2853
the development of metastatic disease in both VSCC and HNSCC 
and as a highly significant independent predictor of poor prog-
nosis in HNSCC. To the best of our knowledge, this is the first 
demonstration of a distinct clinical cancer phenotype associated 
with loss of DAB2. We have begun to extend these studies by pro-
spectively collecting HNSCC samples and analyzing DAB2 expres-
sion levels, using qRT-PCR, and CpG island methylation, using 
quantitative pyrosequencing and MSP analysis. So far our studies 
Figure 7
DAB2 reexpression switches the TGF-β response in vitro and in vivo. (A) Western blotting analysis for DAB2 expression in A431 doxycycline-induc-
ible cell lines. The asterisk indicates cross-reactive bands. A431 TetOn is a clonal derivative of the parental A431 cell line that stably expresses 
the Tet transactivator, from which the 2 DAB2-inducible cell lines were derived (A431 TDAB2#1, A431TDAB2#2). Dab2 expression was assessed 
after treatment with 1 μg/ml doxycycline (Dox) for 24 hours. (B and C) DAB2 expression switches the TGF-β response from promotion to inhibition 
of anchorage-independent growth. (B) Cells were seeded into soft agar, with or without TGF-β and/or doxycycline treatment. Data represent the 
mean ± SD (n = 4). (C) Stable cell lines, described in Figure 4 and Supplemental Figure 8, were seeded into soft agar and treated or not with 1 ng/ml 
TGF-β. Data represent the mean ± SD (n = 3). (D) Stable DAB2 expression switches the TGF-β response from promotion to inhibition of motility. 
Data represent the mean ± SD directional velocity of 8 cells tracked from each of 2 independent wounds. (E and F) DAB2 expression switches the 
TGF-β response in vivo. A431 vector control (E) and a DAB2 stable clone (F) were pretreated and mixed with 1 ng/ml TGF-β and injected into the 
flanks of CD1 nude mice. Tumor volumes were then calculated at the indicated time points for up to 15 days after injection. Data represent the mean 
volume ± SEM (n = 6). Statistical analyses were performed with paired 2-tailed t tests throughout. *P < 0.05, **P < 0.01, ***P < 0.001.
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indicate that MSP+ve samples exhibit quantitatively higher CpG 
island methylation and lower DAB2 expression. Consistent with 
these observations, retrospective analysis of DAB2 expression levels 
determined by microarray analysis in a collected, independent set 
of patients from the UK revealed that low DAB2 levels correlate 
with poor survival. Furthermore, immunohistochemistry analysis 
on a subset of tumors derived from these patients indicated that 
low DAB2 protein levels in the tumor cells themselves also corre-
lated with poor survival, with patients harboring tumors contain-
ing the lowest level of DAB2 expression performing the worst.
Despite the emerging consensus that DAB2 has tumor suppressor 
activity, the mechanistic basis for this is unclear. We observed both 
correlations between loss of DAB2 and the development of meta-
static disease in SCC and between high-level TGFB2 expression and 
poor prognosis. Since TGF-β can act as a potent promoter of metas-
tasis (2, 44) and DAB2 may be involved in TGF-β signaling (14), 
we focused our efforts on investigating the role of DAB2 in TGF-β 
responses. Microarray analysis indicated that HNSCC patients 
expressing a low level of DAB2 and a high level of TGF-β2 exhibited 
the worst prognosis, indicating that loss of DAB2 may modulate 
TGF-β responses. Using a panel of SCC cell lines and DAB2 siRNA 
and reexpression studies, we show that DAB2 is required for TGF-β 
to act as a tumor suppressor in vitro and in vivo. In the presence of 
high/normal levels of DAB2, TGF-β acts to inhibit cell prolifera-
tion, motility, anchorage-independent growth, and tumor growth 
in vivo. Fuchs and coworkers recently demonstrated that targeted 
deletion of TβRII in mouse skin revealed an enhanced motility rate 
in isolated KO fibroblasts (45), and it has been suggested that TGF-β 
may act as a tumor suppressor by regulating “locostasis” (46). Here 
we show that TGF-β can also inhibit tumor cell motility in the pres-
ence of DAB2 and our results strongly support the notion that this 
represents a tumor-suppressive function of TGF-β. Taken together, 
our data indicate that in SCC, TGF-β–mediated tumor suppressive 
actions require DAB2 expression, and we propose that loss of DAB2 
expression by epigenetic or other means may represent an impor-
tant mechanism of resistance to TGF-β–regulated tumor suppres-
sion in many other human tumor types.
Despite the well-documented role of TGF-β as a promoter of 
tumor progression and metastasis (2, 44, 47), the mechanistic 
basis for these properties remains unclear. We demonstrate here 
that downregulation of DAB2 switches the TGF-β response from 
tumor suppressing to tumor promoting and enables TGF-β to pro-
mote proliferation, motility, anchorage-independent growth, and 
tumor growth in vivo. To our knowledge, this is the first example 
of a single epigenetic event that is capable of both abrogating the 
tumor-suppressive function of TGF-β and facilitating the tumor 
promotion function of TGF-β.
Mechanistically, we demonstrate that, unlike previously pub-
lished observations on the HT1080 cell line (14), DAB2 is not 
required for Smad2/3 phosphorylation in MEFs or SCC cell lines. 
Instead, DAB2 acts as a selective endogenous suppressor of TGF-β– 
mediated Smad2 phosphorylation in the tumor cell lines, and 
DAB2 levels inversely correlate with phospho-Smad2 levels in 
HNSCC tumor samples. It remains to be determined whether 
DAB2-mediated selective modulation of Smad signaling dynam-
ics is sufficient to account for the switch of TGF-β responses. 
Support for this possibility comes from the demonstrations that 
siRNA-mediated knockdown of Smad2 attenuates TGF-β–medi-
ated stimulation of cell motility (48) and retroviral transduction 
of dominant-active Smad2 promotes cell migration (49). Further-
more, elevated levels of phospho-Smad2 cooperate with mutant 
Ha-Ras in driving tumor progression and metastasis in a mouse 
model of tumor progression (49), correlate with poor prognosis 
in glioma (47), and are detectable in breast cancer metastases (50). 
Our limited gene analysis indicates that TGF-β–mediated activa-
tion of SnoN and CXCR4 expression is facilitated by loss of DAB2 
expression. Intriguingly, TGF-β–mediated regulation of SnoN is 
Smad2 dependent and is required for TGF-β to promote anchor-
age-independent growth in transformed fibroblasts (40), and 
elevated CXCR4 is a marker of poor prognosis in several human 
tumor types (51). The effect of DAB2 status on the TGF-β tran-
scriptomic response, the contribution of differentially regulated 
target genes to the pro-oncogenic switch in TGF-β signaling, and 
the potential involvement of DAB2 in TGF-β non-Smad signaling 
pathways clearly merit additional study.
The ability of TGF-β to promote malignant progression and 
metastasis implies that it is an attractive pharmacological target 
(52, 53). However, the clinical use of TGF-β inhibitors may be lim-
ited by disruption of the normal homeostatic and tumor suppres-
sor functions of TGF-β. As such, biomarkers predictive of cellular 
response to inhibitors of TGF-β would clearly be valuable. Here 
we present evidence that DAB2 may act as a metastasis suppres-
sor in SCC patients by virtue of its facilitation of the tumor sup-
pressor function of TGF-β and that loss of DAB2 may confer a 
TGF-β–driven promotion of metastatic disease. This may explain 
why patients exhibiting both high-level TGF-β2 expression and 
low-level DAB2 expression exhibit the worst prognosis in our anal-
yses. We therefore propose that patients exhibiting loss of DAB2 
expression are likely to represent prime candidates for the use of 
TGF-β–targeted therapeutics in the management of their disease.
Methods
Plasmids, antibodies, and reagents. pSG5Flag-DAB2 was a gift from Philip Howe 
(Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, 
Cleveland, Ohio, USA) (14). pTRE2pur-DAB2 was generated as described 
in Supplemental Methods. Recombinant human TGF-β1 (Peprotech) was 
resuspended in 1 mM HCl/1 mg/ml BSA and used at appropriate concen-
trations. Antibodies were mouse monoclonals against DAB2 and Smad2/3 
(both from BD Biosciences) and Smad4 (Santa Cruz Biotechnology Inc.); 
rabbit monoclonal against phospho-Smad2 (ser465/476), rabbit polyclonal 
antibodies against phospho-Smad2 (ser465/476), and phospho-Smad3 
(ser433/435) (all from Cell Signaling Technology); and Smad2 and Smad3 
(both from Zymed). Secondary antibodies were HRP-conjugated goat anti-
rabbit Ig (Dako) and HRP-conjugated sheep anti-mouse Ig (Dako).
Cell lines. We used the following squamous carcinoma cell lines: head 
and neck cancer cell lines HN5, HN30, H376, HN76, H413, HSC3, SCC25, 
Proctor, and Delve; vulval cancer cell lines A431, UMSCV1A, UMSCV1B, 
UMSCV2, UMSCV6A, UMSCV7, McKenzie; and ovarian cancer cell line, 
SKOV3. Cell lines were obtained from the CRUK cell line bank and cul-
tured in DMEM supplemented with 10% fetal calf serum, 2 mM l-glu-
tamine, and 100 U/ml penicillin and streptomycin. Stable cell lines were 
generated as described in Supplemental Methods.
Patients and tissues. Human tissues were obtained with informed patient 
consent and with approval of Comitato Etico Azienda Ospedaliera S. 
Croce e Carle for Italian samples and the research ethics committees of 
Kings College London, University of Oxford, and Manchester University, 
Manchester, United Kingdom for the United Kingdom samples. The 
patient population described in Table 1 was composed of patients with 
stage 3 and 4, locally advanced, unresectable squamous carcinomas 
of the head and neck, and tissue samples were collected by the S. Croce 
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General Hospital in Cuneo, Italy, between 1999 and 2005. The patients 
were randomly selected for analysis, and there is, therefore, no selection 
bias. All patients were treated with radical chemoradiotherapy, with 
cisplatin-based chemotherapy regimens. Response to treatment was 
assessed using standard clinical and radiological parameters. The study 
was retrospective and tissues, were obtained as archival, paraffin-embed-
ded specimens. Tissues were usually diagnostic biopsies taken from either 
primary sites of disease or locoregional nodal disease. Vulval squamous car-
cinoma tissue was obtained as resection specimens, from primary sites of 
disease and from inguinal lymph node sites with histologically confirmed 
metastatic disease. The prospective study was performed on 15 patients 
with stage 3 or 4 HNSCC, and tissue samples were collected by S. Croce 
General Hospital. The patient samples analyzed by microarray analysis were 
collected from 71 HNSCC patients with T1-T4 disease from 2 locations 
in the UK and have been described in detail elsewhere (refs. 35 and 54). 
In all cases, the presence of adequate neoplastic tissue in samples for analy-
sis was confirmed by histopathological examination of H&E-stained sec-
tions prior to molecular genetic analysis.
Subtraction PCR. Total RNA was prepared from tissues using RNAzolB 
(Ambion), according to the manufacturer’s instructions. Poly(A)+ RNA 
was subsequently isolated using Poly(A)+ spin columns (New England Bio-
labs). Subtraction PCR was performed with 2 μg poly(A)+ RNA for tester 
and driver using the PCR select system (Clontech), with the modifications 
previously described (55).
Nucleic acid isolation and qRT-PCR. The RNeasy kit (Qiagen) and TRIzol 
were used to isolate total RNA from the relevant cell lines. RNA was obtained 
from paraffin tissue sections using the RecoverAll Total Nucleic Acid Isola-
tion Kit (Ambion), according to the manufacturer’s instructions. Genomic 
DNA was isolated from tissue sections using extended proteinase K diges-
tion. cDNA and qRT-PCR reactions were prepared using the SYBR Green 
2-step qRT-PCR Kit (Finnzymes). Primers for each gene were from Qiagen, 
unless noted otherwise in the Supplemental Methods. Amplified products 
were analyzed by the Chromo4 Continuous Fluorescence Detector (Bio-
Rad) and Opticon Monitor3 software (cell line samples) or the ABI PRISM 
7000 Sequence Detection System (Applied Biosystems) and the Assay-on-
Demand software (Applera) (tumor RNA samples). RNA levels were normal-
ized to 18S rRNA (cell line samples) or β2 microglobulin (tumor samples). 
Uninduced transcript levels were assigned the arbitrary value of 1.
Analysis of CpG methylation, bisulphite sequencing, MSP analysis, and pyrose-
quencing. Genomic DNA was prepared from primary tumor samples, and 
CpG methylation in the DAB2 promoter was analyzed using bisulphite 
sequencing, MSP, and pyrosequencing. DNA (1 μg) was subjected to 
modification with sodium bisulphite, using the EZ DNA methylation kit 
(Zymo) according to the manufacturer’s instruction. Modified DNA was 
then subjected to MSP and bisulphite sequencing. Biotage Sample Prep Kit 
and primers designed for amplifying a 196-bp fragment across the CpG 
island of Dab2 gene and optimized for software dedicated to methylation 
analysis were used for pyrosequencing. After the pyrosequencing run, anal-
ysis was performed using Pyro Q-CpG Software (Biotage). MSP, bisulphite 
sequencing, pyrosequencing primers, and PCR conditions are described in 
Supplemental Methods.
Microarray analysis and data processing. RNAs from the UK primary tumor 
cohort were processed and hybridized to Affymetrix U133Plus2 chips 
(54,675 probe sets/features) at the CRUK microarray facility, Paterson 
Institute. Raw data files are available from the Paterson Institute MIAME-
VICE website (http://bioinformatics.picr.man.ac.uk/vice/PublicProjects.
vice). Three of the seventy-one patients exhibited much longer survival 
times than the rest of the cohort and were therefore excluded from our 
analysis. There were 2, 4, 2, and 6 probes available in the microarray data 
for TGFB1, TGFB2, TGFB3, and DAB2, respectively. First, they were treated 
as continuous variables. Association between probe expression and clini-
cal parameters was examined. Spectral clustering was applied to a gene 
expression matrix of 14 probes to 68 samples in order to observe relation-
ships of these probes (56, 57), followed by calculation of pair-wise corre-
lation, both showing high correlation of between DAB2 probes (Pearson 
correlation 0.77–0.98) and between 3 of TGFB2 probes (Pearson correlation 
0.90–0.95) and no correlation of TGFB1 probes (Pearson correlation –0.07) 
and TGFB3 probes (Pearson correlation –0.12). We carried out univariate 
Cox analysis on all 14 probes and examined Cox PH models involving 3 
variables: pairs of TGFB2 and DAB2 probes and their interaction (all 3 
P values < 0.01, log-rank tests < 0.01). The probes from the best model were 
selected for Kaplan-Meier survival curves. For each of the probes, patients 
were split into high-versus-low expression groups, according to the results 
of an automated search for the most significant discretisation (34). This 
analysis was performed in R and then verified in Partek.
Western blotting. Whole cell lysates and Western blotting were performed 
exactly as previously described (58). Gels were loaded with 50 μg whole 
cell lysate per lane. Bound immunocomplexes were detected by enhanced 
chemiluminescence (ECL; Amersham).
Transfections and siRNA knockdown. Cell lines were transfected with 
plasmids using Lipofectamine 2000 and transient siRNA knockdowns were 
performed using oligofectamine, as recommended by the manufacturers 
(Invitrogen). DAB2 and Silencer Negative control #1 siRNAs (Ambion; see 
Supplemental Methods) or Allstars negative control (Qiagen) were used at 
a final concentration of 50 nM.
[3H]thymidine assays. [3H]thymidine assay cells were seeded into 96-well 
plates and then treated with or without 1 ng/ml TGF-β for 48 hours, fol-
lowed by a 4-hour pulse with 1 μCi [3H]thymidine (GE Healthcare). Cells 
were trypsinized and harvested onto glass fiber filters (Wallac), using a 
Skatron 96-well plate cell harvester (Skatron Instruments). Incorporated 
[3H]thymidine was then measured by scintillation counting, using Opti-
phase Supermix scintillation fluid, 1450 LSC, Luminescence Counter 
Microbeta TriLux (Perkin Elmer).
Wound-healing motility studies. Cell lines were grown to complete confluency 
and then serum starved overnight in DMEM supplemented with 0.1% FCS. 
Wounds were made to the monolayer using a p200 pipette tip, cells were then 
washed in starvation media, and TGF-β was added as appropriate. Wound 
closure was measured by time lapse microscopy. Cells were imaged with a 
×10 objective and an inverted microscope (Axiovert S100, Carl Zeiss Micro-
imaging Inc.) in an atmosphere of 5% CO2 at 37°C. Images were collected 
every 15 minutes for 24 hours, and directional cell motility rates were quan-
tified by image analysis using ImageJ software (http://rsbweb.nih.gov/ij/) 
(Broken Symmetry Software). For siRNA wound-healing studies, cells were 
treated as above 24–48 hours after transfection.
Soft agar assays. Cells were seeded at a density of 2 × 104/well in 6-well 
plates, in growth media supplemented with 0.45% agarose with or without 
TGF-β on top of bottom layer of growth media, supplemented with 0.9% 
agarose in 200 μl DMEM with or without 0.1–1 ng/ml TGF-β, which was 
added to each well twice weekly. Colonies were counted 2–4 weeks after 
seeding. Colonies of more than 80 μm in diameter were scored, and the 
indicated number of 5,250 μM2 fields/well were analyzed using an Olym-
pus CKX41 microscope fitted with a ×4 objective and an eyepiece grati-
cule. Images were captured using a Qimaging Retiga EXi digital camera 
and QCapture Pro software (QImaging Corporation).
Nude mouse xenografts. Nude mouse subcutaneous xenograft experi-
ments were carried out under the UK Animal (Scientific Procedures) Act 
of 1986, with approval from the research ethics committee of University 
of Glasgow. A431V and A431D2#1 cell lines were treated with or without 
1 ng/ml TGF-β for 4 days, harvested, and resuspended in 1xHBSS (Gibco), 
with or without 1 ng/ml TGF-β, at a concentration of 1 × 107 cells per ml. 
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Then, 1 × 106 cells were injected subcutaneously into the flank of CD1 
nude mice (Charles Rivers), and 6 injections per cell line per condition 
were performed. Palpable tumors were observed 8 days after injection, and 
tumor volumes were calculated using calliper measurement and the for-
mula V = (W2 × L)/2, where W is width and L is length.
TMA staining. Immunohistochemistry conditions were optimized on A431 
vector control and DAB2-expressing xenografts for Dab2 and on formalin-
fixed, paraffin-embedded cell pellets for phospho-Smad2. Briefly, 2 × 106 to 
6 × 106 cells were treated with or without 10 μM SB431542 (Tocris) for 15 
minutes, then with or without 1 ng/ml TGF-β for a further hour. Cells were 
washed with PBS and fixed with 10% neutral buffered formalin for 1 hour 
at room temperature. Fixed cells were washed with PBS and resuspended 
in 0.3 ml of 2% agarose. When set, the agarose cell plugs were embedded 
in paraffin. Then, 2.5-μm sections were cut using a microtome (RM2245, 
Leica) and dried for 3 hours at 60°C. Following rehydration, cell pellet 
sections and HNSCC TMA slides (TMA-66, ref. 35, TMA-153, protein bio-
technologies) were subjected to pressure cooker–mediated antigen retrieval 
with EDTA buffer (1.3 mM EDTA, 4.5 mM Tris-Cl, pH 8) for the phospho-
Smad2 antibody and citrate buffer pH 6 (13 mM citric acid, NaOH) for 
the DAB2 antibody. Slides were stained using an autostainer (Dako) and 
1:50 monoclonal anti–phospho-Smad2 (catalog 3108, Cell Signalling) or 
1:100 polyclonal anti-DAB2 (catalog sc-13982, Santa Cruz Biotechnology 
Inc.), using the ImmPRESS anti-rabbit Ig peroxidase Kit (Vector Laborato-
ries), and counterstained with hematoxylin. Protein expression of each core 
was assessed using the weighted histoscore method (59). The weighted his-
toscore grades staining intensity as follows: 0, absent; 1, weak; 2, moderate; 
and 3, strong; then, the grade is multiplied by the percentage of tumor cells 
within each category. Examples of this are shown in Supplemental Figure 3 
for DAB2 and Supplemental Figure 10 for phospho-Smad2.
Statistics. Differences in known prognostic factors between tumors with 
methylated DAB2 promoter and unmethylated DAB2 promoter were 
assessed by use of c2 tests, with continuity corrections where appropriate, 
Mantel-Haenzel c2 tests, and the Kendall’s t-b statistic. Progression-free 
survival was calculated from date of treatment start to date of progression; 
to date of death in patients dying without progression; and to date of cen-
soring in patients alive and progression-free (categorized in Table 1). Over-
all survival was calculated from date of treatment start to date of death 
or date of censoring if alive (categorized in Table 1). Survival curves were 
constructed using Kaplan-Meier methodology. Log-rank tests were used 
in univariate analysis; Cox Proportional Hazards Survival Regression was 
used for multivariate analysis. Comparisons of MSP analysis with pyro-
sequencing, MSP and qRT-PCR, and PO4-Smad2 levels with DAB2 levels 
measured by immunohistochemistry were assessed using nonparametric 
Mann-Whitney U tests. Two-tailed paired t-tests were performed in cell line 
experiments. P values of less than 0.05 were considered significant.
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